Diabetes drug maker Novo Nordisk said on Friday it had agreed a $1.8 billion deal to acquire Emisphere Technologies, giving it control of a pill technology that it hopes will broaden sales to diabetics with an aversion to shots.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,